Summit and Evolva Ink Deal to Develop New Antimicrobials
 
Summit, formerly VASTox, announced this week that it has signed a three-year collaborative agreement with Basel, Switzerland-based Evolva Biotech to develop new drugs for infectious diseases.
 
The collaboration covers Oxford, UK-based Summit’s immunomodulator drug candidate SMT14400 (formerly VOX 14400) and backup compounds from the company’s proprietary imino sugar library.
 

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The apple has traveled westward and eastward along the Silk Road, according to a new genetic analysis.

In Nature this week: GWAS data used to reposition drugs for psychiatric use, and more.

Genetic disease risk information doesn't always spur people to make healthy lifestyle changes, according to the Associated Press.

A University of California, San Diego-led team has used liquid biopsies to uncover possible treatments for patients with cancers of unknown primary.